ArticleThe Journal of clinical endocrinology and metabolism2010
Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Article in The Journal of clinical endocrinology and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01722266 (Liraglutide in the Treatment of Type 1 Diabetes Mellitus), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Who cites it
13 citing papers in PubMed, 50 citations in OpenAlex.
- The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.Journal of endocrinological investigation · 2018Trial
- Article
- Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function.Comprehensive Physiology · 2020Review
- Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.Drugs · 2019Review
- GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner.Diabetes · 2019Article
- The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice.Diabetologia · 2017Article
- Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?Journal of diabetes research · 2016Review
- The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.Diabetologia · 2015Article
- Removal of duodenum elicits GLP-1 secretion.Diabetes care · 2013Article
- Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.Current diabetes reports · 2012Review
- Article
- Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.Journal of medical case reports · 2011Article
- Longstanding insulin dependent diabetics may not require insulin after the introduction of GLP-1 analogues.JRSM cardiovascular diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe mechanism by which glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion is uncertain, and it is not determined whether endogenous insulin is a necessary factor for this effect.
objectiveTo characterize the alpha- and beta-cell responses to GLP-1 in type 1 diabetic patients without residual beta-cell function.
methodsNine type 1 diabetic patients, classified as C-peptide negative by a glucagon test, were clamped at plasma glucose of 20 mmol/liter for 90 min with arginine infusion at time 45 min and concomitant infusion of GLP-1 (1.2 pmol/kg x min) or saline.
resultsInfusion with GLP-1 increased C-peptide concentration just above the detection limit of 33 pmol/liter in one patient, but C-peptide remained immeasurable in all other patients. In the eight remaining patients, total area under the curve of glucagon was significantly decreased with GLP-1 compared with saline: 485 +/- 72 vs. 760 +/- 97 pmol/liter x min (P < 0.001). In addition, GLP-1 decreased the arginine-stimulated glucagon release (incremental AUC of 103 +/- 21 and 137 +/- 16 pmol/liter x min, with GLP-1 and saline, respectively, P < 0.05).
conclusionsIn type 1 diabetic patients without endogenous insulin secretion, GLP-1 decreases the glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia. GLP-1 induced endogenous insulin secretion in one of nine type 1 diabetic patients previously classified as being without endogenous insulin secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.